Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Surgery, East Carolina University, Brody School of Medicine, Greenville, North Carolina.
Surg Obes Relat Dis. 2020 Apr;16(4):457-463. doi: 10.1016/j.soard.2019.12.022. Epub 2020 Jan 3.
Metabolic and bariatric surgery, despite being the only effective durable treatment for obesity, remains underused as approximately 1% of all patients who qualify undergo surgery. The American Society for Metabolic and Bariatric Surgery created a Numbers Taskforce to specify annual rate of utilization for obesity treatment interventions and to determine if patients in need are receiving appropriate therapy.
The objective of this study was to provide the best estimated number of metabolic and bariatric procedure performed in the United States in 2018.
United States.
We reviewed data from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program, National Surgical Quality Improvement Program, Bariatric Outcomes Longitudinal Database, and Nationwide Inpatient Sample. In addition, data from industry and outpatient centers were used to estimate outpatient center activity. Data from 2018 were compared mainly with data from the previous 2 years.
Compared with 2017, the total number of metabolic and bariatric procedures performed in 2018 increased from approximately 228,000 to 252,000. The sleeve gastrectomy continues to be the most common procedure. The gastric bypass procedure trend remained relatively stable and the gastric band procedure trend continued to decline. The percentage of revision procedures and biliopancreatic diversion with duodenal switch procedures increased slightly. Finally, intragastric balloons placement continues as a significant contributor to the cumulative total number of procedures performed but declined from the previous year.
There was a 10.8% increase in the number of metabolic and bariatric procedures performed in 2018, compared with 2017, with an overall increase of approximately 60% since 2011. When taking into account primary procedures only, approximately 1.1% of patients who qualified for metabolic and bariatric surgery were treated with surgery in 2018.
代谢和减重手术是肥胖症的唯一有效持久治疗方法,但由于只有约 1%符合手术条件的患者接受了手术,因此该手术的应用仍不充分。美国代谢和减重外科学会成立了一个数字工作组,以确定肥胖症治疗干预措施的年度使用率,并确定有需要的患者是否接受了适当的治疗。
本研究旨在提供 2018 年美国代谢和减重手术数量的最佳估计值。
美国。
我们回顾了代谢和减重手术认证和质量改进计划、国家手术质量改进计划、减重手术结果纵向数据库和全国住院患者样本的数据。此外,还使用了来自行业和门诊中心的数据来估计门诊中心的活动。将 2018 年的数据与前两年的数据进行了比较。
与 2017 年相比,2018 年进行的代谢和减重手术总数从约 228000 例增加到 252000 例。袖状胃切除术仍然是最常见的手术。胃旁路手术趋势相对稳定,胃带手术趋势继续下降。修订手术和胆胰分流术与十二指肠转位术的比例略有增加。最后,胃内球囊放置仍然是手术总数的一个重要贡献者,但与前一年相比有所下降。
与 2017 年相比,2018 年代谢和减重手术数量增加了 10.8%,自 2011 年以来总体增加了约 60%。仅考虑主要手术,2018 年约有 1.1%符合代谢和减重手术条件的患者接受了手术治疗。